Exelixis, Inc. has grown revenue 13% a year over three years and 18% a year over five, with earnings per share compounding at 84%. Revenue growth, 3-year annual rate: +13% (Biotechnology median +21%). Revenue growth, 5-year rate: +18%, growth has slowed since the five-year average. Earnings per share, 3-year rate: +84%, earnings outgrew revenue: margins or the share count worked for shareholders. Years of annual history on file: 17, FY2009 to FY2025, as filed.

EXELExelixis, Inc.

HealthcareUSD

$56.07

$34.5452 weeks$56.74

Is it growing?

Is EXEL growing?

Exelixis, Inc. has grown revenue 13% a year over three years and 18% a year over five, with earnings per share compounding at 84%.

+13%

Revenue growth, 3-year annual rate · Biotechnology median +21% · steady growth, ahead of inflation · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +18%
Revenue growth, 5-year rate · +13% over three · growth has slowed since the five-year average
Earnings per share, 3-year rate: +84%
Earnings per share, 3-year rate · revenue +13% · earnings outgrew revenue: margins or the share count worked for shareholders
Years of annual history on file: 17
Years of annual history on file · FY2009 to FY2025, as filed